Alebund (礼邦生物) Pre-IPO: Core Product AP301 Phase 3 Update
China-based Alebund Pharmaceuticals seeks to raise $100 million through Hong Kong listing. We provide an up date on core product AP301's Phase 3...
172 Views
Alebund (礼邦生物) Pre-IPO Quick Take: A Niche Renal Specialist
China's Alebund Pharmaceuticals seeks to raise $100 million through a HK listing. The company has an interesting set of products for kidney diseases.
234 Views
ECM Weekly (24 November 2025) - CATL, Hengrui, Hongqiao, WT Micro, SBI Shinsei, NS Group, Ultragreen
Aequitas Research's weekly update on the IPOs, placements, lockup expiry and other ECM linked events that were covered by the team over the past week.
324 Views
ECM Weekly (10 November 2025) - Seres, Pony, WeRide, Joyson, DIY, Maynilad, Northsand, Softcare
Aequitas Research's weekly update on the IPOs, placements, lockup expiry and other ECM linked events that were covered by the team over the past week.
326 Views
No more insights